{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981471098023552.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1089/thy.2013.0078"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/full-xml/10.1089/thy.2013.0078"}},{"identifier":{"@type":"URI","@value":"https://journals.sagepub.com/doi/pdf/10.1089/thy.2013.0078"}}],"dc:title":[{"@value":"Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n                    <jats:title>Background:</jats:title>\n                    <jats:p>Anaplastic thyroid cancer (ATC), a rare highly vascularized tumor, has a dismal outcome. We conducted an open-label study of doublet carboplatin/paclitaxel chemotherapy with or without fosbretabulin in patients with ATC.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:</jats:title>\n                    <jats:p>\n                      Patients were randomly assigned in a 2:1 ratio to 6 cycles of paclitaxel 200 mg/m\n                      <jats:sup>2</jats:sup>\n                      followed by carboplatin AUC 6 on day 1 every 3 weeks (CP), or these drugs were given on day 2 after fosbretabulin 60 mg/m\n                      <jats:sup>2</jats:sup>\n                      (CP/fosbretabulin) on days 1, 8 and 15. After 6 cycles, patients on the fosbretabulin arm without progression could continue to receive fosbretabulin on days 1 and 8 of a 3-week schedule until progression. The primary end point was overall survival (OS).\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:</jats:title>\n                    <jats:p>\n                      Eighty patients were assigned (planned, 180) when enrollment was stopped due to rarity of disease and very low accrual. Median OS was 5.2 months [95% confidence interval (CI) 3.1, 9.0] for the CP/fosbretabulin arm (\n                      <jats:italic toggle=\"yes\">n</jats:italic>\n                      =55; hazard ratio 0.73 [95% CI 0.44, 1.21]) and 4.0 months [95% CI 2.8, 6.2] for the CP arm (\n                      <jats:italic toggle=\"yes\">n</jats:italic>\n                      =25;\n                      <jats:italic toggle=\"yes\">p</jats:italic>\n                      =0.22 [log rank test]). One-year survival for CP/fosbretabulin versus CP was 26% versus 9%, respectively. There was no significant difference in progression-free survival between the two arms. Grade 1–2 hypertension and grade 3–4 neutropenia were more common with CP/fosbretabulin. There were no significant adverse cardiovascular side effects.\n                    </jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:</jats:title>\n                    <jats:p>Although the study did not meet statistical significance in improvement in OS with the addition of fosbretabulin to carboplatin/paclitaxel, it represents the largest prospective randomized trial ever conducted in ATC. The regimen is well tolerated, with AEs and deaths primarily related to ATC and disease progression.</jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981471098023567","@type":"Researcher","foaf:name":[{"@value":"Julie A. Sosa"}],"jpcoar:affiliationName":[{"@value":"Duke University School of Medicine"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023563","@type":"Researcher","foaf:name":[{"@value":"Rossella Elisei"}],"jpcoar:affiliationName":[{"@value":"University of Pisa"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023557","@type":"Researcher","foaf:name":[{"@value":"Barbara Jarzab"}],"jpcoar:affiliationName":[{"@value":"Cancer Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023559","@type":"Researcher","foaf:name":[{"@value":"Jai Balkissoon"}],"jpcoar:affiliationName":[{"@value":"Oxigene, Inc."}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023562","@type":"Researcher","foaf:name":[{"@value":"Shiao-ping Lu"}],"jpcoar:affiliationName":[{"@value":"Oxigene, Inc."}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023552","@type":"Researcher","foaf:name":[{"@value":"Chandrasekhar Bal"}],"jpcoar:affiliationName":[{"@value":"Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India."}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023553","@type":"Researcher","foaf:name":[{"@value":"Shanthi Marur"}],"jpcoar:affiliationName":[{"@value":"Johns Hopkins University"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023560","@type":"Researcher","foaf:name":[{"@value":"Ann Gramza"}],"jpcoar:affiliationName":[{"@value":"National Cancer Institute"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023561","@type":"Researcher","foaf:name":[{"@value":"Rami Ben Yosef"}],"jpcoar:affiliationName":[{"@value":"Tel Aviv Sourasky Medical Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023424","@type":"Researcher","foaf:name":[{"@value":"Barbara Gitlitz"}],"jpcoar:affiliationName":[{"@value":"Norris Comprehensive Cancer Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023564","@type":"Researcher","foaf:name":[{"@value":"Bryan R. Haugen"}],"jpcoar:affiliationName":[{"@value":"University of Colorado"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023566","@type":"Researcher","foaf:name":[{"@value":"Frank Ondrey"}],"jpcoar:affiliationName":[{"@value":"University of Minnesota"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023556","@type":"Researcher","foaf:name":[{"@value":"Charles Lu"}],"jpcoar:affiliationName":[{"@value":"MD Anderson Cancer Center"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023558","@type":"Researcher","foaf:name":[{"@value":"S.M. Karandikar"}],"jpcoar:affiliationName":[{"@value":"Ruby Hall Clinic"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023555","@type":"Researcher","foaf:name":[{"@value":"Fadlo Khuri"}],"jpcoar:affiliationName":[{"@value":"Emory University"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023565","@type":"Researcher","foaf:name":[{"@value":"Lisa Licitra"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology, National Institute for the Study and Care of Tumors, Milan, Italy."}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471098023554","@type":"Researcher","foaf:name":[{"@value":"Scot C. Remick"}],"jpcoar:affiliationName":[{"@value":"West Virginia University School of Medicine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10507256"},{"@type":"EISSN","@value":"15579077"}],"prism:publicationName":[{"@value":"Thyroid®"}],"dc:publisher":[{"@value":"SAGE Publications"}],"prism:publicationDate":"2014-02","prism:volume":"24","prism:number":"2","prism:startingPage":"232","prism:endingPage":"240"},"reviewed":"false","dc:rights":["https://journals.sagepub.com/page/policies/text-and-data-mining-license"],"url":[{"@id":"https://journals.sagepub.com/doi/full-xml/10.1089/thy.2013.0078"},{"@id":"https://journals.sagepub.com/doi/pdf/10.1089/thy.2013.0078"}],"createdAt":"2013-05-30","modifiedAt":"2026-03-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050022476722079872","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Safety and Efficacy of Weekly Paclitaxel Administration for Anaplastic Thyroid Cancer Patients : A Nationwide Prospective Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1050575520347198080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Lenvatinib for Anaplastic Thyroid Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168945874432","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360850094275527040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evaluation of the 8th Edition TNM Classification for Anaplastic Thyroid Carcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1089/thy.2013.0078"},{"@type":"CROSSREF","@value":"10.1089/thy.2016.0072_references_DOI_Y2Maj7nWZqZjT85dQ2rgyoed80L"},{"@type":"CROSSREF","@value":"10.3389/fonc.2017.00025_references_DOI_Y2Maj7nWZqZjT85dQ2rgyoed80L"},{"@type":"CROSSREF","@value":"10.1186/s12885-015-1490-8_references_DOI_Y2Maj7nWZqZjT85dQ2rgyoed80L"},{"@type":"CROSSREF","@value":"10.3390/cancers12030552_references_DOI_Y2Maj7nWZqZjT85dQ2rgyoed80L"}]}